



Innovating for  
affordable healthcare

# Shilpa Medicare Limited

**Manufacturers and Exporters of Bulk Drugs**

Shilpa House # 12-6-214/A-1, Hyderabad Road,  
RAICHUR - 584 135, Karnataka, India.

Phone : +91-8532-238704, Fax : +91-8532-238876

E-mail : info@vbshilpa.com Website : http://www.vbshilpa.com

CIN No. L85110KA1987PLC008739

Date:13/08/2018

To  
Corporate Relationship Department  
BSE Limited,  
1<sup>st</sup> Floor, Rotunda Building,  
P.J. Towers, Dalal Street,  
**Mumbai - 400 001.**

To  
National Stock Exchange of India Limited  
Exchange Plaza, 5<sup>th</sup> Floor,  
Plot No.C/1, G Block  
Bandra Kurla Complex, Bandra (E)  
**MUMBAI - 400 051.**

Dear Sir,

**Sub: Outcome of Board Meeting - Reg.**

**Ref: Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015;**

**Scrip Code: BSE - 530549/ Stock Symbol: NSE - SHILPAMED**

With reference to the captioned subject, Please find the enclosed documents in terms of Regulation 33 of SEBI (LODR) Regulations, 2015:

1. Un-Audited Standalone and Consolidated Financial Results for the first quarter ended 30<sup>th</sup> June, 2018.
2. Limited Review Report on Standalone and Consolidated Financials for the first quarter ended 30<sup>th</sup> June, 2018.

It is further intimated that meeting was commenced at 11:00 A.M. and ended at 2:30 P.M.

This is for your information and necessary records.

**For SHILPA MEDICARE LIMITED,**

  
**MADHUSUDHAN REDDY**  
Company Secretary & Compliance Officer

### STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2018

(Rs. In Lakhs, except per equity share data)

Sl. No.	Particulars	3 months ended	3 months ended	3 months ended	Previous year
		30 Jun, 2018	31 Mar, 2018	30 Jun, 2017	ended 31 Mar, 2018
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
1	<b>Income</b>				
	Revenue from operations (Gross)	18,017.63	21,701.65	15,813.16	74,394.59
	Other Income	395.98	861.08	497.87	2,331.53
	<b>Total Income</b>	<b>18,413.61</b>	<b>22,562.73</b>	<b>16,311.03</b>	<b>76,726.12</b>
2	<b>Expenses</b>				
	a) Cost of material consumed	7,834.90	7,749.14	9,365.46	29,867.96
	b) Purchase of stock-in-trade	126.09	174.81	90.21	586.46
	c) Changes in inventories of finished goods, work-in-progress and Stock-in-Trade	(1,582.41)	2,986.61	(2,065.46)	4,720.58
	d) Employee benefits expense	3,148.21	3,270.60	2,458.35	11,308.10
	e) Finance cost	51.53	58.10	52.81	212.21
	f) Depreciation and amortisation expenses	912.11	963.39	781.86	3,277.70
	g) Excise duty on sales	-	-	-	265.41
	h) Other expenses	2,733.21	2,893.06	2,153.79	9,739.18
	<b>Total Expenses</b>	<b>13,223.64</b>	<b>18,095.71</b>	<b>12,837.02</b>	<b>59,977.60</b>
3	<b>Profit before tax and exceptional items (1)-(2)</b>	<b>5,189.97</b>	<b>4,467.02</b>	<b>3,474.01</b>	<b>16,748.52</b>
4	Exceptional items				
5	<b>Profit Before Tax (3+4)</b>	<b>5,189.97</b>	<b>4,467.02</b>	<b>3,474.01</b>	<b>16,748.52</b>
6	Tax Expense	919.42	994.85	931.78	3,424.64
7	<b>Profit for the Period (5)-(6)</b>	<b>4,270.55</b>	<b>3,472.17</b>	<b>2,542.23</b>	<b>13,323.88</b>
8	<b>Other comprehensive income (OCI)</b>				
	<b>A. Items that will not be reclassified to profit or loss</b>				
	Remeasurement of the defined benefit (liability)/asset	4.22	28.06	(2.77)	16.87
	<b>B. Items that will be reclassified subsequently to profit or loss</b>				
	Gain / (Loss) on derivative instrument (net)	118.89	94.90	(79.24)	91.42
	<b>Total other comprehensive income (net of tax)(A+B)</b>	<b>123.11</b>	<b>122.96</b>	<b>(82.01)</b>	<b>108.29</b>
9	<b>Total comprehensive income for the period / year (7)+(8)</b>	<b>4,393.66</b>	<b>3,595.13</b>	<b>2,460.22</b>	<b>13,432.17</b>
10	Paid up equity share capital (par Value Rs.1/- each, fully paid )	815.27	815.27	801.27	815.27
11	Reserves i.e Other equity				114,882.68
12	<b>Earnings per equity share (par value Rs.1/- each)</b>				
	Basic (Rs.)	5.24	4.41	3.17	16.68
	Diluted (Rs.)	5.24	4.41	3.17	16.68

For and on behalf of the Board of Directors



Vishnukant.C. Bhutada  
Managing Director

Date: 13/08/2018

Place: Hyderabad



Innovating for  
affordable healthcare

## Shilpa Medicare Limited

Registered office : # 12-6-214/A-1, Hyderabad Road, Raichur -584135

Website - www.vbshilpa.com, Email - info@vbshilpa.com., Telephone -+91-8532-238494

CIN No. - L85110KA1987PLC008739

### STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2018

(Rs. in Lakhs, except per equity share data)

Sl No.	Particulars	3 months ended	3 months ended	3 months	Previous year
		30 Jun, 2018	31 Mar, 2018	ended	ended 31 Mar,
		(Unaudited)	(Audited)	30 Jun, 2017	2018
				(Unaudited)	(Audited)
1	<b>Income</b>				
	Revenue from operations	19,816.54	23,445.82	16,586.58	79,153.39
	Other Income	435.89	678.05	487.52	2,167.76
	<b>Total Income</b>	<b>20,252.43</b>	<b>24,123.87</b>	<b>17,074.10</b>	<b>81,321.15</b>
2	<b>Expenses</b>				
	a) Cost of material consumed	8,136.01	7,961.51	9,489.52	30,794.70
	b) Purchase of stock-in-trade	123.78	176.15	91.09	588.70
	c) Changes in inventories of finished goods, work-in-progress and Stock-in-Trade	(1,207.74)	2,587.82	(2,158.98)	4,204.16
	d) Employee benefits expense	4,047.69	4,241.63	3,304.06	14,913.88
	e) Finance cost	57.87	104.50	55.21	266.12
	f) Depreciation and amortisation expenses	1,025.92	1,077.25	907.16	3,722.21
	g) Excise duty on sales	-	-	-	270.75
	h) Other expenses	3,244.43	3,733.17	2,600.41	12,164.85
	<b>Total Expenses</b>	<b>15,427.96</b>	<b>19,882.03</b>	<b>14,288.47</b>	<b>66,925.37</b>
3	<b>Profit before share of profit of joint venture and associates, exceptional items and tax (1)- (2)</b>	<b>4,824.47</b>	<b>4,241.84</b>	<b>2,785.63</b>	<b>14,395.78</b>
4	Share of Profit / (loss) of Joint venture and associates, net of tax	(545.81)	(155.25)	279.40	(719.03)
5	<b>Profit before tax and exceptional items (3-4)</b>	<b>4,278.66</b>	<b>4,086.59</b>	<b>3,065.03</b>	<b>13,676.75</b>
6	Exceptional items	-	-	-	-
7	<b>Profit Before Tax (5+6)</b>	<b>4,278.66</b>	<b>4,086.59</b>	<b>3,065.03</b>	<b>13,676.75</b>
8	Tax Expense	963.88	1,022.96	901.85	3,390.57
9	<b>Profit for the Period / year before non-controlling interest (7)-(8)</b>	<b>3,314.78</b>	<b>3,063.63</b>	<b>2,163.18</b>	<b>10,286.18</b>
10	Share of (loss)/profit attributable to non-controlling interest	(49.26)	(26.75)	(53.57)	(238.00)
11	<b>Profit after taxes attributable to owners of the Parent Company for the period / year (9-10)</b>	<b>3,364.04</b>	<b>3,090.38</b>	<b>2,216.75</b>	<b>10,524.18</b>
12	<b>Other comprehensive income (OCI)</b>				
	<b>A. Items that will not be reclassified to profit or loss</b>				
	Remeasurement of the defined benefit liability/asset Gain/(Loss) (net of tax)	4.22	29.32	(2.77)	18.13
	<b>B. Items that will be reclassified subsequently to profit or loss</b>				
	Gain / (Loss) on derivative instrument (net of tax)	118.89	94.90	(79.24)	91.42
	<b>Total other comprehensive income(net of tax)(A+B)</b>	<b>123.11</b>	<b>124.22</b>	<b>(82.01)</b>	<b>109.55</b>
13	<b>Total comprehensive income for the period / year (11)+(12)</b>	<b>3,487.15</b>	<b>3,214.60</b>	<b>2,134.74</b>	<b>10,633.73</b>
14	Paid up equity share capital (par Value Rs.1/- each, fully paid )	815.27	815.27	801.27	815.27
15	Reserves i.e other equity				107,688.04
16	<b>Earnings per equity share (par value Rs.1/- each)</b>				
	Basic (Rs.)	4.13	3.94	2.77	13.20
	Diluted (Rs.)	4.13	3.94	2.77	13.20

#### Notes:

- The unaudited standalone and consolidated financial results for the quarter ended Jun 30, 2018 in respect of Shilpa Medicare Limited ("the Company") have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on Aug 13, 2018. The above results have been subjected to limited review by the statutory auditors of the Company.
- These financial results have been prepared in accordance with Indian Accounting Standards (Ind-AS) prescribed under section 133 of the Companies Act 2013 read with the relevant rules there under and in terms of Regulation 33 of SEBI (Listing Obligation and Other Disclosure Requirements) Regulations, 2015 and SEBI Circular dated 5th July 2016.
- Effective April 1, 2018, the Company adopted Ind AS 115 "Revenue from Contracts with Customers" and applied prospectively to contracts with customers existing as on 1st April, 2018. The applicability of Ind AS 115 did not have any significant impact on recognition and measurement of revenue and related items in the financial results of the Company.
- The figures for the quarter ended March 31, 2018 are the balancing figures between audited figures in respect of the full previous financial year and the published unaudited year to date figures upto the third quarter of the previous financial year. Also, the figures up to the end of the previous year third quarter were subjected to limited review.
- Post Implementation of GST w.e.f July 01, 2017, revenue from operations is disclosed net of GST. Revenue from operation for the earlier period i.e quarter ended Jun 30, 2017 and for the previous year ended March 31, 2018 includes excise upto Jun 30, 2017 which is now subsumed in the GST. Accordingly revenue from operation for the quarter ended March 31, 2018 & Jun 30, 2017 are not comparable.
- During the previous year, the Company has allotted 13,99,994 nos. equity shares of Rs.1/- to shares holders of Navya Biological Pvt. Ltd., Hubli pursuant to scheme of amalgamation by the order of "The National Company Law Tribunal, Bengaluru Bench, Bengaluru" dated 24.11.2017 with appointed date 01.04.2016.
- Standalone other income includes dividend accrued on preference shares held by Company in subsidiaries/joint ventures which has been reinstated and the impact of same is considered in the above result.
- The Operating segment of the Company is " Pharmaceuticals", as the Chief Operating Decision maker review business performance at an overall Company level as one segment. Therefore, segment reporting as per Ind-AS 108 is not applicable to the Company.
- Comparative figures have been regrouped/ reclassified wherever necessary to confirm the current quarter classification.

For and on behalf of the Board of Directors

Vishnukant.C. Bhutada  
Managing Director

Date: 13/08/2018  
Place: Hyderabad



CHARTERED ACCOUNTANTS

VIJAYAWADA, HYDERABAD, VISAKHAPATNAM, GUNTUR, KAKINADA, TANUKU, ALSO AT CHENNAI, BANGALORE AND ADONI.

### Limited Review Report – Standalone Financial Results

**To the Board of Directors of Shilpa Medicare Limited,**

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of **SHILPA MEDICARE LIMITED** (“the Company”) for the quarter ended 30th June, 2018 (the “statement”) being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.

This statement is the responsibility of the Company’s Management and has been approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 “Interim Financial Reporting”, prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statement based on our review.

2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Review of Interim Financial information performed by the Independent Auditor of the Entity, issued by Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free from material misstatements. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. The figures for quarter ended 30th June 2017 included in this statement under report were reviewed/audited by another firm of Chartered Accountants, who were the immediate preceding statutory auditors, who expressed an unmodified conclusion thereon. Our conclusion is not modified in respect of the said matter.





*Brahmayya & Co.,*

CHARTERED ACCOUNTANTS

VIJAYAWADA, HYDERABAD, VISAKHAPATNAM, GUNTUR, KAKINADA, TANUKU, ALSO AT CHENNAI, BANGALORE AND ADONI.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Indian Accounting Standards (Ind AS) and other recognized accounting principles and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place : Hyderabad  
Date : 13.08.2018

for **BRAHMAYYA & CO.**  
Chartered Accountants  
Firm's Regn No. 000513S



*K. Shrawan*  
**(K.SHRAVAN)**  
Partner  
Membership No. 215798



**Limited Review Report – Consolidated Financial Results**

**To the Board of Directors of Shilpa Medicare Limited,**

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial results of SHILPA MEDICARE LIMITED (“the Company”) its subsidiaries (the Company and its subsidiaries together referred to as ‘the Group’), its associates and joint Ventures for the quarter ended 30th June, 2018 (the “statement”), being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.

This statement is the responsibility of the Company’s Management and has been approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 “Interim Financial Reporting”, prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the statement based on our review.

2. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, Review of Interim Financial information performed by the Independent Auditor of the Entity, issued by Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free from material misstatements. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. The Statement includes the result of the following Subsidiaries/ Associates/Joint Venture:
  - a. Koanaa Healthcare Limited, UK (Wholly owned subsidiary Company)
  - b. Koanaa Healthcare Limited, Austria (Wholly owned subsidiary Company)
  - c. Zatortia Holdings Limited (Wholly Owned Subsidiary Company)
  - d. Shilpa Therapeutics Private Limited ( Wholly Owned Subsidiary Company)
  - e. INM Technologies Private Limited (Subsidiary Company)
  - f. INM Nuvent Paints Private Limited (Step down Subsidiary Company)
  - g. Loba Feinchemie,Gmbh (Step down Subsidiary Company)
  - h. Makindus, Inc (Subsidiary Company)
  - i. Raichem Medicare Private Limited (Joint Venture Company)





*Brahmayya & Co.,*

CHARTERED ACCOUNTANTS

VIJAYAWADA, HYDERABAD, VISAKHAPATNAM, GUNTUR, KAKINADA, TANUKU, ALSO AT CHENNAI, BANGALORE AND ADONI.

- j. MAIA Pharmaceuticals, Inc (Associate Company)
  - k. Reva Medicare Private Limited (Joint Venture Company)
  - l. Reva Pharmachem Private Limited (Associate Company)
4. We did not review the financial results of above Subsidiaries included in the Statement whose financial results reflect total revenue of Rs. 2005.41 lakhs (before elimination) and net Loss of Rs. 384.08 lakhs (before elimination) for the quarter ended 30th June 2018.  
We did not review the financial results of above Joint Ventures and Associates whose financial results reflect company's share of net loss of Rs. 545.81 lakhs for the quarter ended 30th June 2018.  
These financial results have been prepared and furnished to us by the management and our opinion on the consolidated financial results, in so far as it relates to the amounts included in respect of these subsidiaries, Joint Ventures and Associates are based solely on such unaudited financial statements.
5. The figures for quarter ended 30th June 2017 included in this statement under report were reviewed by another firm of Chartered Accountants, who were the immediate preceding statutory auditors, who expressed an unmodified conclusion thereon.
6. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited Consolidated Financial Results prepared in accordance with applicable Indian Accounting Standards (Ind AS) and other recognized accounting principles and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

for **BRAHMAYYA & CO.**  
Chartered Accountants  
Firm's Regn No. 000513S



*K. Shrawan*  
**(K.SHRAVAN)**

Partner

Membership No. 215798

Place : Hyderabad  
Date : 13.08.2018